HROW
HROW
NASDAQ · Pharmaceuticals

Harrow Inc

$39.99
+0.07 (+0.18%)
As of Aug 8, 1:38 AM ET ·
Financial Highlights (FY 2026)
Revenue
279.22M
Net Income
-5,269,698
Gross Margin
75.0%
Profit Margin
-1.9%
Rev Growth
+45.4%
D/E Ratio
4.64
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.0% 75.0% 63.9% 63.9%
Operating Margin 8.4% 7.5% 23.6% 21.0%
Profit Margin -1.9% -1.8% 15.6% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 279.22M 192.05M 753.50M 775.29M
Gross Profit 209.56M 144.13M 481.22M 495.14M
Operating Income 23.34M 14.45M 178.06M 162.96M
Net Income -5,269,698 -3,262,073 117.60M 129.68M
Gross Margin 75.0% 75.0% 63.9% 63.9%
Operating Margin 8.4% 7.5% 23.6% 21.0%
Profit Margin -1.9% -1.8% 15.6% 16.7%
Rev Growth +45.4% +45.4% +23.8% +22.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 619.99M 619.99M 692.61M 691.25M
Total Equity 133.71M 133.71M 1.12B 1.10B
D/E Ratio 4.64 4.64 0.62 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 25.31M 16.54M 185.25M 214.55M
Free Cash Flow 80.89M 86.69M